14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.

摘要: OBJECTIVE: Bisphosphonates are effective treatment for osteoporosis but have been associated with gastrointestinal (GI) mucosal injury. This study compared the incidence of gastric ulcers after risedronate, a pyridinyl bisphosphonate, or alendronate, primary amino in healthy postmenopausal women stratified by Helicobacter pylori status. METHODS: Subjects were randomized to receive risedronate 5 mg (n = 318) alendronate 10 317) daily 14 days. Endoscopy and evaluator-blind assessments esophageal, gastric, duodenal mucosa performed at baseline on Days 8 15. RESULTS: Overall, > 3 mm observed 18 (6.0%) 300 evaluable subjects group 36 (12.1%) 297 during (p 0.013). On Day 8, incidences groups 3.6% 6.6%, respectively 0.133), 15, they 3.3% 8.7% 0.008). The was not affected H. Mean endoscopy scores 15 significantly lower than